If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Oreste Villani is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 15 Similar Profiles
Multiple Myeloma Medicine & Life Sciences
Myelodysplastic Syndromes Medicine & Life Sciences
Retrospective Studies Medicine & Life Sciences
Frail Elderly Medicine & Life Sciences
B-Cell Chronic Lymphocytic Leukemia Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Azacitidine Medicine & Life Sciences
Salvage Therapy Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2007 2018

  • 620 Citations
  • 14 h-Index
  • 34 Article

Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)

Musto, P., Simeon, V., Cascavilla, N., Falcone, A., Petrucci, M. T., Cesini, L., Di Raimondo, F., Conticello, C., Ria, R., Catalano, L., Salvatore, D., Mastrullo, L., Gagliardi, A., Villani, O., Pietrantuono, G., D'Arena, G., Mansueto, G., Bringhen, S., Genuardi, M., Di Renzo, N. & 8 others, Reddiconto, G., Fragasso, A., Caravita, T., Scapicchio, D., Marziano, G., Boccadoro, M., Mangiacavalli, S. & Corso, A., Oct 23 2018, In : Annals of Hematology.

Research output: Contribution to journalArticle

Salvage Therapy
Multiple Myeloma
Therapeutics
Recurrence
Drug Combinations

Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)

Musto, P., Simeon, V., Cascavilla, N., Falcone, A., Petrucci, M. T., Cesini, L., Di Raimondo, F., Conticello, C., Ria, R., Catalano, L., Salvatore, D., Mastrullo, L., Gagliardi, A., Villani, O., Pietrantuono, G., D’Arena, G., Mansueto, G., Bringhen, S., Genuardi, M., Di Renzo, N. & 8 others, Reddiconto, G., Fragasso, A., Caravita, T., Scapicchio, D., Marziano, G., Boccadoro, M., Mangiacavalli, S. & Corso, A., Jan 1 2018, (Accepted/In press) In : Annals of Hematology.

Research output: Contribution to journalArticle

Salvage Therapy
Multiple Myeloma
Therapeutics
Recurrence
Drug Combinations
8 Citations (Scopus)

Epha3 acts as proangiogenic factor in multiple myeloma

Caivano, A., La Rocca, F., Laurenzana, I., Annese, T., Tamma, R., Famigliari, U., Simeon, V., Trino, S., Luca, L. D., Villani, O., Berardi, S., Basile, A., Vacca, A., Saglio, G., Del Vecchio, L., Musto, P. & Cilloni, D., 2017, In : Oncotarget. 8, 21, p. 34298-34309 12 p.

Research output: Contribution to journalArticle

Ephrin-A3
Eph Family Receptors
Multiple Myeloma
Endothelial Cells
Small Interfering RNA
5 Citations (Scopus)

EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells

la Rocca, F., Airoldi, I., Di Carlo, E., Marotta, P., Falco, G., Simeon, V., Laurenzana, I., Trino, S., de Luca, L., Todoerti, K., Villani, O., Lackmann, M., D’Auria, F., Frassoni, F., Neri, A., Del Vecchio, L., Musto, P., Cilloni, D. & Caivano, A., 2017, In : Cellular Oncology. 40, 5, p. 483-496 14 p.

Research output: Contribution to journalArticle

Multiple Myeloma
Growth
Plasma Cells
Cell Survival
In Vitro Techniques
5 Citations (Scopus)

EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells

La Rocca, F., Airoldi, I., Di Carlo, E., Marotta, P., Falco, G., Simeon, V., Laurenzana, I., Trino, S., De Luca, L., Todoerti, K., Villani, O., Lackmann, M., D'Auria, F., Frassoni, F., Neri, A., Del Vecchio, L., Musto, P., Cilloni, D. & Caivano, A., Oct 2017, In : Cellular oncology (Dordrecht). 40, 5, p. 483-496 14 p.

Research output: Contribution to journalArticle

Multiple Myeloma
Growth
Plasma Cells
Cell Survival
In Vitro Techniques